Tumor Biology

, Volume 36, Issue 4, pp 2277–2285 | Cite as

miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1

Research Article


MicroRNAs (miRNAs) are a class of non-protein-coding small RNAs with the capacity to regulate fundamental biological processes essential for cancer initiation and progression. In the present study, we analyzed miRNA expression levels between multidrug-resistant gastric carcinoma cell line SGC7901/ADR and its parent cell line SGC7901 using a miRNA microarray. MiR-103/107 was downregulated compared with parental SGC7901 cells. Overexpression of miR-103/107 sensitized SGC7901/ADR cells to doxorubicin (DOX), as demonstrated by in vitro and in vivo drug sensitivity assay. We further confirmed that miR-103/107 inhibited P-gp function in gastric cancer SGC7901/ADR cells. Finally, we verified that caveolin-1 (Cav-1), a critical component of lipid rafts, was a target of miR-103/107.


Gastric carcinoma miR-103/107 Multidrug resistance Caveolin-1 



This work was supported by the National Science and Technology Major Project (grant no. 2013ZX09303002), the Chinese National Foundation of National Sciences (grant nos. 81270036, 81372485, 81372546, and 81472193), the Science and Technology project of Liaoning Province (grant no. 2013021057), and the Colleges and Universities of Liaoning Province Outstanding Talent Support Plan (grant no. LR2014023).

Conflicts of interest



  1. 1.
    Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev. 2013;39:60–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Anderson AC, Pollastri MP, Schiffer CA, Peet NP. The challenge of developing robust drugs to overcome resistance. Drug Discov Today. 2011;16:755–61.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des. 2013;19:7126–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Papp E, Gadawski I, Côté HC. Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells. J Antimicrob Chemother. 2008;61:1048–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 2008;7:670–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011;162:1096–108.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Guo Q, Nan XX, Yang JR, Yi L, Liang BL, Wei YB, et al. Triptolide inhibits the multidrug resistance in prostate cancer cells via the downregulation of MDR1 expression. Neoplasma. 2013;60:598–604.CrossRefPubMedGoogle Scholar
  8. 8.
    Nath S, Daneshvar K, Roy LD, Grover P, Kidiyoor A, Mosley L, et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis. 2013;2:e51.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Neelakandan K, Babu P, Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr Cancer Drug Targets. 2012;12:716–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Krützfeldt J, Poy MN, Stoffel M. Strategies to determine the biological function of microRNAs. Nat Genet. 2006;38:S14–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Hong L, Yang Z, Ma J, Fan D. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets. 2013;14:1118–27.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. 2012;29:2527–34.CrossRefPubMedGoogle Scholar
  14. 14.
    Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog. 2013;52:70–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Li H, Hui L, Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai). 2012;44:269–77.CrossRefGoogle Scholar
  16. 16.
    Zhang S, Wan Y, Pan T, Gu X, Qian C, Sun G, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012;47:346–56.CrossRefPubMedGoogle Scholar
  17. 17.
    Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer. 2011;2:720–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29:384–91.CrossRefPubMedGoogle Scholar
  19. 19.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Liu J, Zhang Y, Qu J, Xu L, Hou K, Zhang J, et al. β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer. 2011;11:183.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y, et al. Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol. 2009;218:248–55.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang Y, Mu X, Li E, Luo Y, Song N, Qu X, et al. The role of E3 ubiquitin ligase Cbl proteins in β-Elemene reversing multi-drug resistance of human leukemia and gastric cancer cells. Int J Mol Sci. 2013;14:10075–89.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–53.CrossRefPubMedGoogle Scholar
  24. 24.
    Yun UJ, Lee JH, Koo KH, Ye SK, Kim SY, Lee CH, et al. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Biochem Pharmacol. 2013;85:1441–53.CrossRefPubMedGoogle Scholar
  25. 25.
    Orlowski S, Martin S, Escargueil A. P-glycoprotein and ‘lipid rafts’: some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell Mol Life Sci. 2006;63:1038–59.CrossRefPubMedGoogle Scholar
  26. 26.
    Bacso Z, Nagy H, Goda K, Bene L, Fenyvesi F, Matkó J, et al. Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A. 2004;61:105–16.CrossRefPubMedGoogle Scholar
  27. 27.
    Modok S, Heyward C, Callaghan R. P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment. J Lipid Res. 2004;45:1910–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 2012;15:98–105.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13:326–46.CrossRefPubMedGoogle Scholar
  30. 30.
    Park J, Bae E, Lee C, Yoon SS, Chae YS, Ahn KS, et al. RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol. 2010;31:643–50.CrossRefPubMedGoogle Scholar
  31. 31.
    Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, Bhat MK. Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One. 2013;8:e61524.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59:105–10.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Ye Zhang
    • 1
  • Xiujuan Qu
    • 1
  • Ce Li
    • 1
  • Yibo Fan
    • 1
  • Xiaofang Che
    • 1
  • Ximing Wang
    • 2
  • Ying Cai
    • 1
  • Xuejun Hu
    • 2
  • Yunpeng Liu
    • 1
  1. 1.Department of Medical OncologyThe First Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Respiratory MedicineThe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations